Impact of prior cancer history on survival of patients with gastric cancer |
| |
| Affiliation: | 1. Department of Prenatal Diagnosis and Screening Center, Hangzhou Women’s Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, Zhejiang, 310008, China;2. Department of Head, Neck & Thyroid Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, 310000, China;3. Department of Radiology, The 903 Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army, Hangzhou, Zhejiang, 310000, China;4. Department of Breast Surgery, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, 310000, China;1. Department of Gynecology and Obstetrics of Parma, 43125, Parma, Italy;2. Department of Gynecologic Oncology, ARNAS Civico Di Cristina Benfratelli, Palermo, Italy;1. Department of Surgical Oncology, Homi Bhabha Cancer Hospital, Varanasi, India;2. Colorectal Division, Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, India;1. National Centre for Peritoneal Malignancy, Department of Surgery, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland;2. Department of Hepatobiliary Surgery, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland;3. Department of Anaesthesiology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland;4. Basingstoke and North Hampshire Hospital, Peritoneal Malignancy Institute, Basingstoke, UK;1. Department of Surgery, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada;2. Department of Surgery, University of Montreal, Montreal, QC, Canada;3. Department of Gynecology & Obstetrics, University of Montreal, Montreal, QC, Canada;1. Division of Thoracic Surgery, Brigham and Women''s Hospital, Boston, MA, USA;2. Department of Thoracic Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China;3. Department of Data Sciences, Dana Farber Cancer Institute, Boston, USA;4. Department of Pathology, Brigham and Women''s Hospital, Boston, MA, USA |
| |
| Abstract: | ![]()
BackgroundPatients with prior cancer history are commonly excluded from clinical trial. However, the impact of prior cancer on survival of patients with gastric cancer remains largely unknown. The aim of this study was to evaluate the prevalence of prior cancer and assess its impact on survival of patients diagnosed with gastric cancer.MethodsPatients with gastric cancer as the primary or second primary malignancies diagnosed from 2004 to 2010 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM) was conducted to balance baseline characteristics. Kaplan-Meier method, multivariate Cox proportional hazard model, and multivariate competing risk model were performed for survival analysis.ResultsA total of 28,795 eligible patients with gastric cancer were included, of whom 2695 (9.35%) had a history of prior cancer. Prostate (35%), breast (12%), colon (8%), and urinary bladder (7%) malignancies were the most common prior cancer types. Patients with prior cancer history had slightly inferior overall survival (AHR = 1.06; 95% CI [1.00–1.12]; P = 0.043) but superior gastric cancer-specific survival (AHR = 0.82; 95% CI [0.76–0.88]; P < 0.001) compared with those without prior cancer. The subgroup analysis determined that a prior cancer history did not adversely affect gastric patients’ clinical outcomes, except in those with prior cancer diagnosed within one year, at distant stage, or originating from lung and bronchus.ConclusionA substantial proportion of gastric cancer patients with a history of prior cancer had non-inferior clinical outcome to those without prior cancer. These patients should be considered in clinical trials. |
| |
| Keywords: | Gastric cancer Prior cancer Survival SEER Trial eligibility |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
